Q2 2025 Natera Inc Earnings Call Transcript
Key Points
- Natera Inc (NTRA) reported a 32% year-over-year revenue growth, reaching $547 million in Q2 2025.
- The company achieved a record volume of 189,000 oncology tests processed in the quarter, marking a significant milestone.
- Gross margin improved to 63.4% in Q2 2025, up from approximately 59% in the same quarter last year.
- Natera Inc (NTRA) raised its revenue guidance by $80 million, now expecting revenues between $2.02 billion and $2.1 billion for the year.
- The company launched Fetal Focus, a new NIPT for inherited conditions, leveraging its proprietary SNP-based method.
- Despite strong growth, Natera Inc (NTRA) faces challenges in achieving consistent revenue true-ups due to their lumpiness and difficulty in forecasting.
- The company is not increasing its operating expenses, which may limit its ability to scale rapidly despite being in full investment mode.
- Natera Inc (NTRA) faces potential risks in expanding coverage for non-covered tumor types, which could impact future revenue growth.
- The company is investing heavily in AI and MRD-related projects, which may not yield immediate revenue and could strain resources.
- There is uncertainty around the timeline for gaining Medicare coverage for non-covered histologies, which could delay expected revenue contributions.
Hello. Welcome to Natera's 2025 second-quarter financial results conference call. (Operator Instructions)
As a reminder, this conference call is being recorded today, August 7, 2025. I would now like to turn the conference call over to Michael Brophy, Chief Financial Officer. Please go ahead.
Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our second quarter of 2025. On the line, I'm joined by Steve Chapman, our CEO; Solomon Moshkevich, President, Clinical Diagnostics; and Alex Aleshin, General Manager of Oncology and our Chief Medical Officer. Today's conference call is being broadcast live via webcast.
We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available. Starting on Slide 2. During the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
